CHICAGO — For years, scientists said creating a drug around the KRAS protein was impossible. On Monday, Amgen (AMGN) showed it had developed a medicine that shrank tumors in 50% of lung cancer patients.

These lung cancer patients — just 10 of them because this is an early-stage clinical trial — all had tumors that tested positive for a particular mutation in KRAS, a cell-signaling protein. The 50% response rate to AMG 510 is an improvement over the 30% response rate first reported by Amgen last month. It also exceeds investor expectations.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • “The results: Five out of 10 evaluable lung cancer patients had partial responses; another four had stable disease. All five of the responders remain on AMG 510 with treatment durations ranging from seven weeks to seven months.”
    I found this sentence quite confusing and unclear: what does exactly “evaluable” stay for? You wrote “5 out of 10 had partial response, another 4 had stable disease” does it mean they did not responded? it did not progress?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy